Immunogenicity of recombinant hepatitis b vaccine in urban black children from ga-rankuwa, bophuthatswana, south africa

Peter T. Manyike; Sanet Aspinall; Robert S. Summers

doi:10.1097/00006454-199209000-00011

Immunogenicity of recombinant hepatitis b vaccine in urban black children from ga-rankuwa, bophuthatswana, south africa

Peter T. Manyike, Sanet Aspinall^*, Robert S. Summers

^*Corresponding author for this work

Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Many areas in Southern Africa have a relatively high endemicity for hepatitis B for which the only effective medical measure is vaccination. The aim of this study was to evaluate the antibody response to a recombinant hepatitis B vaccine (Engerix B®; Smith Kline-Beecham) in a black urban population, with the use of the recommended regimen and a low dose, short course. One hundred eleven children seronegative for hepatitis B virus (5 to 19 years old) were randomized to receive one of the two vaccination schedules (20 μg at zero, 1 and 6 months or 2 μg at zero, 1 and 2 months).

Original language	English
Pages (from-to)	726-730
Number of pages	5
Journal	Pediatric Infectious Disease Journal
Volume	11
Issue number	9
DOIs	https://doi.org/10.1097/00006454-199209000-00011
Publication status	Published - Sept 1992

Keywords

Black children
Hepatitis B vaccine
Immunogenicity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00006454-199209000-00011

Cite this

@article{600fb420c5cb43a2a1ab45cf12d270c9,

title = "Immunogenicity of recombinant hepatitis b vaccine in urban black children from ga-rankuwa, bophuthatswana, south africa",

abstract = "Many areas in Southern Africa have a relatively high endemicity for hepatitis B for which the only effective medical measure is vaccination. The aim of this study was to evaluate the antibody response to a recombinant hepatitis B vaccine (Engerix B{\textregistered}; Smith Kline-Beecham) in a black urban population, with the use of the recommended regimen and a low dose, short course. One hundred eleven children seronegative for hepatitis B virus (5 to 19 years old) were randomized to receive one of the two vaccination schedules (20 μg at zero, 1 and 6 months or 2 μg at zero, 1 and 2 months).",

keywords = "Black children, Hepatitis B vaccine, Immunogenicity",

author = "Manyike, {Peter T.} and Sanet Aspinall and Summers, {Robert S.}",

year = "1992",

month = sep,

doi = "10.1097/00006454-199209000-00011",

language = "English",

volume = "11",

pages = "726--730",

journal = "Pediatric Infectious Disease Journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - Immunogenicity of recombinant hepatitis b vaccine in urban black children from ga-rankuwa, bophuthatswana, south africa

AU - Manyike, Peter T.

AU - Aspinall, Sanet

AU - Summers, Robert S.

PY - 1992/9

Y1 - 1992/9

N2 - Many areas in Southern Africa have a relatively high endemicity for hepatitis B for which the only effective medical measure is vaccination. The aim of this study was to evaluate the antibody response to a recombinant hepatitis B vaccine (Engerix B®; Smith Kline-Beecham) in a black urban population, with the use of the recommended regimen and a low dose, short course. One hundred eleven children seronegative for hepatitis B virus (5 to 19 years old) were randomized to receive one of the two vaccination schedules (20 μg at zero, 1 and 6 months or 2 μg at zero, 1 and 2 months).

AB - Many areas in Southern Africa have a relatively high endemicity for hepatitis B for which the only effective medical measure is vaccination. The aim of this study was to evaluate the antibody response to a recombinant hepatitis B vaccine (Engerix B®; Smith Kline-Beecham) in a black urban population, with the use of the recommended regimen and a low dose, short course. One hundred eleven children seronegative for hepatitis B virus (5 to 19 years old) were randomized to receive one of the two vaccination schedules (20 μg at zero, 1 and 6 months or 2 μg at zero, 1 and 2 months).

KW - Black children

KW - Hepatitis B vaccine

KW - Immunogenicity

UR - http://www.scopus.com/inward/record.url?scp=0026722582&partnerID=8YFLogxK

U2 - 10.1097/00006454-199209000-00011

DO - 10.1097/00006454-199209000-00011

M3 - Article

C2 - 1448312

AN - SCOPUS:0026722582

SN - 0891-3668

VL - 11

SP - 726

EP - 730

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

IS - 9

ER -

Immunogenicity of recombinant hepatitis b vaccine in urban black children from ga-rankuwa, bophuthatswana, south africa

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this